Protection by Thiazolidinediones in Myocardial Ischemia
噻唑烷二酮类药物对心肌缺血的保护作用
基本信息
- 批准号:6436621
- 负责人:
- 金额:$ 28.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-02-01 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:bioenergetics carbohydrate metabolism cytoprotection glucose transport glucose transporter heart disorder chemotherapy heart function heart metabolism hypoglycemic agents insulin sensitivity /resistance myocardial infarct sizing myocardial ischemia /hypoxia nonhuman therapy evaluation oxidative phosphorylation oxidative stress peroxisome proliferator activated receptor pharmacokinetics receptor expression swine troglitazone tumor necrosis factor alpha
项目摘要
DESCRIPTION (provided by applicant): Thiazolidinediones are ligands of the
peroxisome proliferator associated receptor (PPAR)-gamma, a key orchestrator of
cellular energy substrate metabolism. Thiazolidinediones are used clinically to
treat Type II diabetes. This laboratory has demonstrated that chronic treatment
of normal, non-diabetic pigs with a thiazolidinedione drug improves recovery of
left ventricular function after ischemia and reperfusion in vivo.
This project will test the hypothesis that thiazolidinediones improve recovery
of cardiac function after ischemia and reduce myocardial infarct size through
specific alterations of myocardial gene expression and energy substrate
metabolism that are coupled to PPAR-gamma activation. In particular, it is
hypothesized that chronic thiazolidinedione treatment of non-diabetic pigs
improves recovery of cardiac function after ischemia and reperfusion by:
1. Increasing myocardial expression of glucose transporters GLUT1 and GLUT4,
thereby facilitating glucose uptake and enhancing myocardial insulin
sensitivity
2. Increasing the oxidation of carbohydrate substrates in reperfused myocardium
3. Increasing myocardial expression of uncoupling protein-2, which may serve to
mitigate oxidant injury during reperfusion
4. Decreasing myocardial expression of pro-inflammatory and negative inotropic
cytokines, such as tumor necrosis factor-alpha
If the proposed studies confirm these salutary effects of PPAR-gamma activation
with thiazolidinediones, the results may suggest an important new treatment
strategy for patients with ischemic heart disease, even those without diabetes.
描述(由申请人提供): 噻唑烷二酮类是以下配体
过氧化物酶体增殖物相关受体(PPAR)-γ,是
细胞能量底物代谢。噻唑烷二酮类药物临床上用于
治疗 II 型糖尿病。该实验室已证明慢性治疗
使用噻唑烷二酮药物改善正常非糖尿病猪的恢复
体内缺血和再灌注后的左心室功能。
该项目将测试噻唑烷二酮类药物可改善恢复的假设
缺血后的心脏功能并减少心肌梗死面积
心肌基因表达和能量底物的特异性改变
与 PPAR-γ 激活相关的代谢。特别是,它是
假设对非糖尿病猪进行长期噻唑烷二酮治疗
通过以下方式改善缺血和再灌注后心脏功能的恢复:
1.增加心肌葡萄糖转运蛋白GLUT1和GLUT4的表达,
从而促进葡萄糖摄取并增强心肌胰岛素
灵敏度
2. 增加再灌注心肌中碳水化合物底物的氧化
3. 增加心肌解偶联蛋白2的表达,这可能有助于
减轻再灌注过程中的氧化损伤
4. 减少促炎和负性肌力的心肌表达
细胞因子,例如肿瘤坏死因子-α
如果拟议的研究证实 PPAR-gamma 激活的这些有益作用
对于噻唑烷二酮类药物,结果可能表明一种重要的新治疗方法
针对缺血性心脏病患者(甚至没有糖尿病的患者)的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GREGORY G SCHWARTZ其他文献
GREGORY G SCHWARTZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GREGORY G SCHWARTZ', 18)}}的其他基金
Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
饮食引起的猪胰岛素抵抗和心肌缺血
- 批准号:
8069630 - 财政年份:1994
- 资助金额:
$ 28.35万 - 项目类别:
Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
饮食引起的猪胰岛素抵抗和心肌缺血
- 批准号:
7618190 - 财政年份:1994
- 资助金额:
$ 28.35万 - 项目类别:
Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
饮食引起的猪胰岛素抵抗和心肌缺血
- 批准号:
7845092 - 财政年份:1994
- 资助金额:
$ 28.35万 - 项目类别:
Protection by Thiazolidinediones in Myocardial Ischemia
噻唑烷二酮类药物对心肌缺血的保护作用
- 批准号:
6604250 - 财政年份:1994
- 资助金额:
$ 28.35万 - 项目类别:
Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
饮食引起的猪胰岛素抵抗和心肌缺血
- 批准号:
8280242 - 财政年份:1994
- 资助金额:
$ 28.35万 - 项目类别:
Protection by Thiazolidinediones in Myocardial Ischemia
噻唑烷二酮类药物对心肌缺血的保护作用
- 批准号:
7087019 - 财政年份:1994
- 资助金额:
$ 28.35万 - 项目类别:
相似海外基金
Elucidating the role of hepatic mTORC2 as a key regulator of carbohydrate metabolism in non-alcoholic fatty liver disease
阐明肝脏 mTORC2 作为碳水化合物代谢关键调节因子在非酒精性脂肪肝中的作用
- 批准号:
10548816 - 财政年份:2022
- 资助金额:
$ 28.35万 - 项目类别:
Elucidating the role of hepatic mTORC2 as a key regulator of carbohydrate metabolism in non-alcoholic fatty liver disease
阐明肝脏 mTORC2 作为碳水化合物代谢关键调节因子在非酒精性脂肪肝中的作用
- 批准号:
10387520 - 财政年份:2022
- 资助金额:
$ 28.35万 - 项目类别:
Molecular basis for elucidating the mechanism of carbohydrate metabolism in higher fungi to reduce energy consumption
阐明高等真菌碳水化合物代谢降低能量消耗机制的分子基础
- 批准号:
20K05794 - 财政年份:2020
- 资助金额:
$ 28.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Contribution of carbohydrate metabolism to the maintenance of endemic streptococcal pathogens
碳水化合物代谢对地方性链球菌病原体维持的贡献
- 批准号:
nhmrc : GNT1165876 - 财政年份:2019
- 资助金额:
$ 28.35万 - 项目类别:
Project Grants
CAREER: Evolutionary Genomics of Enzymes for Complex Carbohydrate Metabolism
职业:复杂碳水化合物代谢酶的进化基因组学
- 批准号:
1933521 - 财政年份:2019
- 资助金额:
$ 28.35万 - 项目类别:
Continuing Grant
Exploration of carbohydrate metabolism in hyperthermophilic archaea: novel approaches, enzymes and metabolic pathways
超嗜热古菌碳水化合物代谢的探索:新方法、酶和代谢途径
- 批准号:
381206548 - 财政年份:2018
- 资助金额:
$ 28.35万 - 项目类别:
Research Grants
Study on cyclic polyol-based carbohydrate metabolism regulatory molecules
基于环状多元醇的碳水化合物代谢调节分子的研究
- 批准号:
18K06725 - 财政年份:2018
- 资助金额:
$ 28.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alveolar epithelial carbohydrate metabolism in acute lung injury
急性肺损伤时肺泡上皮碳水化合物代谢
- 批准号:
10320406 - 财政年份:2018
- 资助金额:
$ 28.35万 - 项目类别:
Alveolar epithelial carbohydrate metabolism in acute lung injury
急性肺损伤时肺泡上皮碳水化合物代谢
- 批准号:
10080101 - 财政年份:2018
- 资助金额:
$ 28.35万 - 项目类别:
CAREER: Evolutionary Genomics of Enzymes for Complex Carbohydrate Metabolism
职业:复杂碳水化合物代谢酶的进化基因组学
- 批准号:
1652164 - 财政年份:2017
- 资助金额:
$ 28.35万 - 项目类别:
Continuing Grant